Table 2.
Univariable and multivariable Cox regression models for the prediction of institutionalization and mortality in SCD/MCI patients
| Institutionalization | Mortality | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Model 1 | Model 2 | Univariable | Model 1 | Model 2 | |||||
| Age and sex adjusted | Without CSF | Without CSF/MRI | Age and sex adjusted | Without CSF | Without CSF/MRI | |||||
| Age |
1.09* (1.05; 1.13) |
1.10* (1.06; 1.14) |
1.03 (1.00; 1.07) |
1.07 (1.02; 1.11) |
1.10 (1.06; 1.14) |
1.12* (1.09; 1.16) |
1.12* (1.09; 1.15) |
1.04 (1.00; 1.07) |
1.06 (1.02; 1.09) |
1.08 (1.05; 1.12) |
| Sex, female |
1.21 (0.73; 2.00) |
1.35 (0.81; 2.23) |
1.52 (0.98; 2.60) |
1.67 (1.00; 2.83) |
1.56 (0.92; 2.63) |
0.72 (0.49; 1.06) |
0.75 (0.51; 1.10) |
0.97 (0.64; 1.45) |
0.96 (0.65; 1.43) |
0.88 (0.59; 1.32) |
| MMSE |
0.83* (0.77; 0.90) |
0.83* (0.76; 0.91) |
0.91 (0.83; 1.00) |
0.84 (0.77; 0.91) |
0.84 (0.77; 0.92) |
0.94 (0.88; 1.01) |
0.95 (0.88; 1.02) |
|||
| NPI |
1.03* (1.00; 1.06) |
1.03* (1.01; 1.06) |
1.03 (1.00; 1.06) |
1.03 (1.00; 1.06) |
1.03* (1.01; 1.05) |
1.02* (1.00; 1.04) |
1.02 (1.00; 1.04) |
1.02 (1.00; 1.04) |
||
| CCI |
1.22* (1.07; 1.39) |
1.00 (0.81; 1.23) |
1.50* (1.38; 1.63) |
1.29* (1.15; 1.46) |
1.27 (1.12; 1.43) |
1.23 (1.09; 1.39) |
1.28 (1.14; 1.45) |
|||
| APOE e4 |
1.96* (1.18; 3.27) |
1.91* (1.15; 3.19) |
1.67 (1.00; 2.79) |
1.85 (1.10; 3.09) |
1.36 (0.94; 1.96) |
1.32 (0.91; 1.90) |
||||
| GCA |
2.74* (1.92; 3.92) |
2.21* (1.45; 3.36) |
2.08 (1.34; 3.23) |
2.08 (1.32; 3.26) |
2.93* (2.27; 3.80) |
1.89* (1.39; 2.56) |
1.39 (0.97; 1.97) |
1.46 (1.03; 2.06) |
||
| MTA |
1.89* (1.34; 2.58) |
1.36 (0.91; 2.04) |
2.52* (2.04; 3.12) |
1.76* (1.37; 2.27) |
1.50 (1.11; 2.01) |
1.44 (1.08; 1.93) |
||||
| WMH |
1.60* (1.20; 2.13) |
1.25 (0.91; 1.71) |
1.47* (1.19; 1.82) |
1.08 (0.85; 1.37) |
||||||
| CSF Aβ42a |
0.85* (0.80; 0.90) |
0.87* (0.82; 0.92) |
0.90 (0.84; 0.96) |
0.92* (0.89; 0.96) |
0.95* (0.92; 0.99) |
0.96 (0.92; 1.00) |
||||
| CSF p-tau |
1.05* (1.04; 1.06) |
1.04* (1.02; 1.05) |
1.02 (1.01; 1.04) |
1.03* (1.02; 1.04) |
1.02* (1.00; 1.03) |
1.02 (1.00; 1.03) |
||||
| Harrell’s C |
0.81 (0.76; 0.86) |
0.76 (0.71; 0.82) |
0.76 (0.70; 0.82) |
0.79 (0.75; 0.83) |
0.79 (0.75; 0.83) |
0.76 (0.71; 0.80) |
||||
| 3-year Brier score |
0.015 (0.008; 0.021) |
0.015 (0.008; 0.021) |
0.015 (0.008; 0.021) |
0.024 (0.016; 0.032) |
0.0244 (0.016; 0.032) |
0.024 (0.016; 0.032) |
||||
Data is represented as Hazard Ratio (95%CI) and Harrell’s C (95%CI)
We used all variables as continuous variables in the models, except for the dichotomous variables gender and APOE e4
AD Alzheimer’s disease, 95%CI 95% confidence interval, NPI Neuropsychiatric Inventory, MMSE Mini-Mental State Examination, CCI Charlson Comorbidity Index, GCA global cortical atrophy, MTA medial temporal lobe atrophy, WMH white matter hyperintensities, CSF cerebrospinal fluid, Aβ42 β-Amyloid 1–42, p-tau Tau phosphorylated at threonine 181
aHazard ratio for every 100 pg/ml
*p<0.05 in univariate analysis